Drug Profile
Sym 015
Alternative Names: Anti-Met; S-95027; Sym-015Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Symphogen
- Developer Servier; Symphogen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Lung cancer; Solid tumours
Highest Development Phases
- Phase II Non-small cell lung cancer; Solid tumours
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 02 Feb 2022 Phase-II clinical trials in Non-small cell lung cancer (Parenteral) (Servier pipeline, February 2022)
- 31 Dec 2020 Symphogen completes phase I/II clinical trial in Lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Denmark, Hong Kong, South Korea, Spain, Taiwan (Parenteral) in December 2020 (NCT02648724) (EudraCT2016-003912-11)